NCT01110291: Induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1353-1362

  Hilli, Johanna ^a,b   Sailas, Liisa ^c   Jyrkkiö, Sirkku ^b   Pyrhönen, Seppo ^b   Laine, Kari ^a,b,d  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

^d Medbase Oy Ltd   (Finland)

Author keywords

CYP3A activity; Dexamethasone; Docetaxel; Induction; Peroral midazolam

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; MIDAZOLAM; TROPISETRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDAZOLAM; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS;

EID: 79959584649     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1426-6     Document Type: Article

References (24)

1. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229-239 (Pubitemid 40450714)
2. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Breast Cancer International Research Group 001 Investigators et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
3. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671 (Pubitemid 46631307)
4. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, National Surgical Adjuvant Breast Bowel Project Protocol B-27 (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
5. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690 (Pubitemid 34983229)
6. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258 (Pubitemid 30226205)
7. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401 (Pubitemid 28475303)
8. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598-2603 (Pubitemid 30482093)
9. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172 (Pubitemid 26300483)
10. Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14:147-151 (Pubitemid 26340683)
11. Lin Y, Anderson GD, Kantor E, Ojemann LM, Wilensky AJ (1999) Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol 39:578-582 (Pubitemid 30629037)
12. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302 (Pubitemid 26080972)
13. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355-2370
14. Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG, Hawke RL (2008) The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 36:1465-1469
15. Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N (2001) Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 48:42-46 (Pubitemid 32662435)
16. Kostrubsky VE, Lewis LD, Strom SC, Wood SG, Schuetz EG, Schuetz JD, Sinclair PR, Wrighton SA, Sinclair JF (1998) Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 355:131-136 (Pubitemid 28364360)
17. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970 (Pubitemid 46631397)
18. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ, Leukemia Cancer B Group (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-3311 (Pubitemid 46944916)
19. Bruno R, Vivier N, Houver C, Montay G, Riva A (1996) Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics. Ann Oncol 7(Suppl. 1):96 (A335)
20. Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K (2006) Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 29:779-784
21. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570-580
22. Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Hérait P, Pons G, Treluyer JM, Goldwasser F (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 18:168-172 (Pubitemid 46152518)
23. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M (2007) A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 97:1338-1343 (Pubitemid 350114792)
24. Puisset F, Alexandre J, Treluyer JM, Raoul V, Roché H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97:290-296 (Pubitemid 47196745)